Results 41 to 50 of about 7,390 (165)

Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile

Медицинский совет, 2019
Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The article presents data on the clinical and MRI efficacy
D. L. Klabukova, M. V. Davydovskaya
doaj   +1 more source

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review

Annals of Clinical and Translational Neurology, 2023
Across its clinical development program, ocrelizumab demonstrated efficacy in improving clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed disability progression.
Xavier Montalban, Paul M. Matthews, Alex Simpson, John L. Petrie, Cormac Sammon, Sreeram Ramagopalan, Giulio Disanto, Jens Kuhle   +7 more
doaj   +1 more source

Secondary Organising Pneumonia Among Immunocompromised Multiple Sclerosis Patients Treated With Ocrelizumab Following COVID‐19 Infection: Two Case Reports With Literature Review

Respirology Case Reports
Anti‐CD20 medications, such as rituximab and coronavirus disease 2019 (COVID‐19) infection, have been shown to cause secondary organising pneumonia (OP).
Tarake M. Aljarod, Richard Scott Morehead   +1 more
doaj   +1 more source

Late-onset severe neutropenia in patients with relapsing remitting multiple sclerosis treated with ocrelizumab: case report and literature review

Frontiers in Neuroscience
ObjectiveTo describe two cases of recurrent, delayed-onset severe neutropenia several months following ocrelizumab therapy in patients with relapsing–remitting multiple sclerosis (RRMS).BackgroundA rare adverse effect of ocrelizumab is neutropenia, with ...
Catherine Tauro, Zeinab Awada, Radhika Malhotra, Asaff Harel   +3 more
doaj   +1 more source

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi, Sola Al Ghazal, Salem Hannoun, Medhat A. Siddik, Nour M. Najjar, Jim Dagher, Joseph Abboud, Myriam G. Semaan, Samia J. Khoury   +8 more
wiley   +1 more source

Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis

, 2023
Background: The majority of patients with multiple sclerosis on ocrelizumab have B-cell depletion after standard interval dosing of 26 weeks. With B-cell-guided dosing patients receive their next dose when B-cell repopulation occurs. Prediction of B-cell
Toorop, Alyssa A., Hogenboom, Laura, Kocyigit, Merve, Wijnants, Anne, Strijbis, Eva M. M., Bloem, Karien, Killestein, Joep, Rispens, Theo, Lissenberg-Witte, Birgit I., Commandeur, Nadine W. M., Uitdehaag, Bernard M. J., van Kempen, Zoé L. E.   +11 more
core   +1 more source

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto, Dariia Kliushnikova, Richard Friedrich Radlberger, Sinan Yasaroglu, Tobias Moser, Andrea Harrer, Kitty Kratzer, Wolfgang Hitzl, Christiane Gradl, Martin Schmidauer, Patrick Roth, Harald Hegen, Peter Wipfler   +12 more
wiley   +1 more source

First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report

Case Reports in Neurology
Background: Leukocytoclastic vasculitis (LCV) is a small vessel vasculitis primarily affecting the skin, and its association with specific drugs is not widely documented.
Mohammadali Nahayati, Mina Farahnezhad, Amir Khanmirzaei, Fatemeh Khosravani   +3 more
doaj   +1 more source

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population

Annals of Clinical and Translational Neurology, 2021
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited.
Eva Fernandez‐Diaz, Jose A. Perez‐Vicente, Ramon Villaverde‐Gonzalez, Leticia Berenguer‐Ruiz, Antonio Candeliere Merlicco, Maria Luisa Martinez‐Navarro, Julia Gracia Gil, Carlos M. Romero‐Sanchez, Arantxa Alfaro‐Saez, Inmaculada Diaz, Juana Gimenez‐Martinez, Maria Angeles Mendez‐Miralles, Jorge Millan‐Pascual, Javier Jimenez‐Pancho, Santiago Mola, Angel P. Sempere   +15 more
doaj   +1 more source

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine, Fabien Rollot, Romain Casey, Nicolas Collongues, Sandra Vukusic, Guillaume Mathey, Anne Laure Dubessy, Jonathan Ciron, Jérôme De Seze, Aurélie Ruet, Pierre Labauge, Arnaud Kwiatkowski, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun‐Frenay, David Axel Laplaud, Eric Berger, Eric Thouvenot, Jean Pelletier, Abdullatif Al Khedr, Olivier Casez, Bertrand Bourre, Abir Wahab, Laurent Magy, Jean‐Philippe Camdessanché, Ines Doghri, Solène Moulin, Mariana Sarov Rivière, Karolina Hankiewicz, Amélie Dos Santos, Corinne Pottier, Eric Manchon, Jennifer Aboab, Maia Tchikviladze, Thomas David, Gilles Edan, Emmanuelle Le Page, Laure Michel, Anne Kerbrat, OFSEP Investigators   +40 more
wiley   +1 more source